Friebe, Astrid <br/><br/>
Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)  Apr 2007 
 - 333-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1524-9557 
<br/><br/><label>Standard No.: </label>10.1097/01.cji.0000211346.19330.c9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Biomarkers--blood<br/>Depression--diagnosis<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--adverse effects<br/>Interleukin-4 Receptor alpha Subunit--blood<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neopterin--blood<br/>Prognosis<br/>Receptors, Interleukin-6--blood<br/>Receptors, Tumor Necrosis Factor, Type I--blood<br/>Recombinant Proteins<br/>Skin Neoplasms--drug therapy<br/>Th1 Cells--immunology<br/>Th2 Cells--immunology